Traws Pharma Stock Fundamentals
| TRAW Stock | 5.02 0.31 5.82% |
Traws Pharma fundamentals help investors to digest information that contributes to Traws Pharma's financial success or failures. It also enables traders to predict the movement of Traws Stock. The fundamental analysis module provides a way to measure Traws Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Traws Pharma stock.
At this time, Traws Pharma's Total Other Income Expense Net is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 9.7 M in 2024, whereas Total Revenue is likely to drop slightly above 193.2 K in 2024. Traws | Select Account or Indicator |
Traws Pharma Company Return On Equity Analysis
Traws Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Traws Pharma Return On Equity | -10.97 |
Most of Traws Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Traws Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Traws Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Traws Pharma has a Return On Equity of -10.9652. This is 54.25% lower than that of the Pharmaceuticals sector and 69.93% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Traws Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Traws Pharma's current stock value. Our valuation model uses many indicators to compare Traws Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Traws Pharma competition to find correlations between indicators driving Traws Pharma's intrinsic value. More Info.Traws Pharma is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At this time, Traws Pharma's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Traws Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Traws Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Traws Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics of similar companies.Traws Pharma is currently under evaluation in return on equity category among its peers.
Traws Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Traws Pharma from analyzing Traws Pharma's financial statements. These drivers represent accounts that assess Traws Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Traws Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 136.7M | 2.0B | 1.1B | 339.8M | 414.5M | 434.3M | |
| Enterprise Value | 113.9M | 2.0B | 1.0B | 301.0M | 393.7M | 412.8M |
Traws Fundamentals
| Return On Equity | -10.97 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (103.23) % | ||||
| Current Valuation | (8.03 M) | ||||
| Shares Outstanding | 25.31 M | ||||
| Shares Owned By Insiders | 14.62 % | ||||
| Shares Owned By Institutions | 11.40 % | ||||
| Number Of Shares Shorted | 7.71 K | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 39.17 X | ||||
| Revenue | 226 K | ||||
| EBITDA | (20.28 M) | ||||
| Net Income | (18.95 M) | ||||
| Total Debt | 12.01 M | ||||
| Book Value Per Share | (4.17) X | ||||
| Cash Flow From Operations | (17.93 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (5.95) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 8.85 M | ||||
| Total Asset | 22.68 M | ||||
| Retained Earnings | (482.63 M) | ||||
| Working Capital | 13.44 M | ||||
| Net Asset | 22.68 M |
About Traws Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 203.4 K | 180.8 K | |
| Total Revenue | 203.4 K | 193.2 K | |
| Cost Of Revenue | 16 K | 16.1 K | |
| Stock Based Compensation To Revenue | 5.76 | 6.04 | |
| Sales General And Administrative To Revenue | 40.24 | 42.25 | |
| Research And Ddevelopement To Revenue | 50.50 | 53.03 | |
| Capex To Revenue | 0.07 | 0.12 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (89.81) | (94.30) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.